Chloroprocaine Spinal Anesthesia for Cervical Cerclage (CP Spinal)
Primary Purpose
Adverse Reaction to Spinal Anesthetic, Maternal Care for Cervical Incompetence
Status
Completed
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
Chloroprocaine
Bupivacaine
Fentanyl
Saline
Sponsored by
About this trial
This is an interventional other trial for Adverse Reaction to Spinal Anesthetic focused on measuring Chloroprocaine, cervical cerclage, spinal anesthesia, Bupivacaine
Eligibility Criteria
Inclusion Criteria:
- ASA I and II women
- 18-45 yrs old
- Singleton pregnancy
- Cervical cerclage 1st or 2nd trimester of pregnancy undergoing with spinal anesthesia
- Height 150 - 180 cm
- BMI ≤ 40 kg/m2.
Exclusion Criteria:
- Any contraindication to neuraxial anesthesia (history of neurologic disease (e.g., multiple sclerosis, spinal stenosis, central or peripheral neuropathy)
- Pre-existing/chronic back pain
- Ester local anesthetic allergy, PABA allergy
- History of atypical cholinesterase (CP is metabolized by cholinesterase)
Sites / Locations
- New York Presbyterian Hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
Chloroprocaine (CP)
Bupivacaine (BUP)
Arm Description
Patients in CP group will receive 3% 2-chloroprocaine 50 mg (1.67 ml) and fentanyl 15 mcg (0.3 ml)
Patients in BUP group will receive hyperbaric 0.75% bupivacaine 9 mg (1.4 ml), with fentanyl 15 mcg (0.3 ml), with saline (0.3 ml) to bring the volume to ~ 2 ml
Outcomes
Primary Outcome Measures
Time to Resolution of Motor Block
The mean difference between groups in time between the end of spinal injection (t IT) to time for no motor block (t motor), i.e. tIT - T motor. Motor block will be assessed using the Bromage scale:
Bromage Scale I = free movement of the legs and feet = no block II = able to flex knees, with free movement of feet = partial (33%) block III = unable to flex knees, but with free movement of the feet = almost complete (66%) block IV = unable to move legs or feet = complete block (100%)
Secondary Outcome Measures
Time to Ambulate
Time from spinal anesthesia placement to ability to ambulate.
Time to Void
Time from spinal anesthesia injection to ability to void spontaneously.
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT02862912
Brief Title
Chloroprocaine Spinal Anesthesia for Cervical Cerclage (CP Spinal)
Official Title
Chloroprocaine Versus Bupivacaine Spinal Anesthesia for Cervical Cerclage
Study Type
Interventional
2. Study Status
Record Verification Date
December 2020
Overall Recruitment Status
Completed
Study Start Date
November 8, 2016 (Actual)
Primary Completion Date
January 31, 2020 (Actual)
Study Completion Date
January 31, 2020 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Columbia University
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
This study aims to determine whether or not spinal anesthesia with the local anesthetic drug, chloroprocaine, wears off faster than the local anesthetic drug, bupivacaine, and results in faster discharge from the post-anesthesia care unit after surgery.
Detailed Description
This will be a prospective, randomized, double blind clinical trial. Subjects will be ASA I and II women ≥18 yrs old with a singleton pregnancy in the 1st or 2nd trimester of pregnancy undergoing cervical cerclage with spinal anesthesia. Patients will be randomly allocated to the chloroprocaine (CP) or bupivacaine group (BUP). Patients will receive spinal anesthesia with either chloroprocaine 50 mg with fentanyl 15 mcg or bupivacaine 9 mg with fentanyl 15 mcg.
Bupivacaine is the most common local anesthetic used for cervical cerclage with spinal anesthesia. Bupivacaine is safe and has been preferred over other medications such as lidocaine, because it is associated with a low incidence of a complication from spinal anesthesia known as "transient neurologic symptoms" - a condition where pain and cramping in the buttocks and lower extremities can be experienced for several days. Bupivacaine is a long-acting local anesthetic agent and therefore has the disadvantage of a prolonged anesthetic recovery that may last a few hours.
Chloroprocaine is a local anesthetic with a fast onset and short duration that may be used for spinal anesthesia for ambulatory procedures. Chloroprocaine is currently used at the research institution for spinal anesthesia for ambulatory surgical patients, especially for lower extremity orthopedic procedures such as knee arthroscopy, as well as for pregnant patients.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Adverse Reaction to Spinal Anesthetic, Maternal Care for Cervical Incompetence
Keywords
Chloroprocaine, cervical cerclage, spinal anesthesia, Bupivacaine
7. Study Design
Primary Purpose
Other
Study Phase
Phase 4
Interventional Study Model
Factorial Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
43 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Chloroprocaine (CP)
Arm Type
Experimental
Arm Description
Patients in CP group will receive 3% 2-chloroprocaine 50 mg (1.67 ml) and fentanyl 15 mcg (0.3 ml)
Arm Title
Bupivacaine (BUP)
Arm Type
Active Comparator
Arm Description
Patients in BUP group will receive hyperbaric 0.75% bupivacaine 9 mg (1.4 ml), with fentanyl 15 mcg (0.3 ml), with saline (0.3 ml) to bring the volume to ~ 2 ml
Intervention Type
Drug
Intervention Name(s)
Chloroprocaine
Other Intervention Name(s)
Nesacaine
Intervention Description
Administered as a single injection or continuously through an indwelling catheter - 50 mg
Intervention Type
Drug
Intervention Name(s)
Bupivacaine
Other Intervention Name(s)
Bupivacaine hydrochloride
Intervention Description
A dextrose Solution is usually given as an injection - 9 mg (1.4 ml)
Intervention Type
Drug
Intervention Name(s)
Fentanyl
Other Intervention Name(s)
Sublimaze
Intervention Description
15 mcg Fentanyl will be included int he spinal anesthetic in both groups
Intervention Type
Drug
Intervention Name(s)
Saline
Other Intervention Name(s)
Salt water
Intervention Description
Preservative free normal saline (0.3 ml) to bring the volume to ~ 2 ml
Primary Outcome Measure Information:
Title
Time to Resolution of Motor Block
Description
The mean difference between groups in time between the end of spinal injection (t IT) to time for no motor block (t motor), i.e. tIT - T motor. Motor block will be assessed using the Bromage scale:
Bromage Scale I = free movement of the legs and feet = no block II = able to flex knees, with free movement of feet = partial (33%) block III = unable to flex knees, but with free movement of the feet = almost complete (66%) block IV = unable to move legs or feet = complete block (100%)
Time Frame
3 hours
Secondary Outcome Measure Information:
Title
Time to Ambulate
Description
Time from spinal anesthesia placement to ability to ambulate.
Time Frame
5 hours
Title
Time to Void
Description
Time from spinal anesthesia injection to ability to void spontaneously.
Time Frame
5 hours
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
ASA I and II women
18-45 yrs old
Singleton pregnancy
Cervical cerclage 1st or 2nd trimester of pregnancy undergoing with spinal anesthesia
Height 150 - 180 cm
BMI ≤ 40 kg/m2.
Exclusion Criteria:
Any contraindication to neuraxial anesthesia (history of neurologic disease (e.g., multiple sclerosis, spinal stenosis, central or peripheral neuropathy)
Pre-existing/chronic back pain
Ester local anesthetic allergy, PABA allergy
History of atypical cholinesterase (CP is metabolized by cholinesterase)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Richard Smiley, MD
Organizational Affiliation
Columbia University
Official's Role
Principal Investigator
Facility Information:
Facility Name
New York Presbyterian Hospital
City
New York
State/Province
New York
ZIP/Postal Code
10032
Country
United States
12. IPD Sharing Statement
Plan to Share IPD
Yes
IPD Sharing Plan Description
A research report will be written and submitted to a peer-reviewed journal
IPD Sharing Time Frame
Submission will be made by December, 2020. Publication availability is to be determined by the peer review process. Once published, the data should be available indefinitely.
IPD Sharing Access Criteria
To be determined.
Citations:
PubMed Identifier
24601887
Citation
Camponovo C, Wulf H, Ghisi D, Fanelli A, Riva T, Cristina D, Vassiliou T, Leschka K, Fanelli G. Intrathecal 1% 2-chloroprocaine vs. 0.5% bupivacaine in ambulatory surgery: a prospective, observer-blinded, randomised, controlled trial. Acta Anaesthesiol Scand. 2014 May;58(5):560-6. doi: 10.1111/aas.12291. Epub 2014 Mar 6.
Results Reference
background
PubMed Identifier
21288208
Citation
Hejtmanek MR, Pollock JE. Chloroprocaine for spinal anesthesia: a retrospective analysis. Acta Anaesthesiol Scand. 2011 Mar;55(3):267-72. doi: 10.1111/j.1399-6576.2010.02371.x.
Results Reference
background
PubMed Identifier
34153006
Citation
Lee A, Shatil B, Landau R, Menon P, Smiley R. Intrathecal 2-Chloroprocaine 3% Versus Hyperbaric Bupivacaine 0.75% for Cervical Cerclage: A Double-Blind Randomized Controlled Trial. Anesth Analg. 2022 Mar 1;134(3):624-632. doi: 10.1213/ANE.0000000000005653.
Results Reference
derived
Learn more about this trial
Chloroprocaine Spinal Anesthesia for Cervical Cerclage (CP Spinal)
We'll reach out to this number within 24 hrs